Authors:
Zheng, GZ
Lee, CH
Pratt, JK
Perner, RJ
Jiang, MQ
Gomtsyan, A
Matulenko, MA
Mao, Y
Koenig, JR
Kim, KH
Muchmore, S
Yu, HX
Kohlhaas, K
Alexander, KM
McGaraughty, S
Chu, KL
Wismer, CT
Mikusa, J
Jarvis, MF
Marsh, K
Kowaluk, EA
Bhagwat, SS
Stewart, AO
Citation: Gz. Zheng et al., Pyridopyrimidine analogues as novel adenosine kinase inhibitors, BIOORG MED, 11(16), 2001, pp. 2071-2074
Authors:
Cowart, M
Lee, CH
Gfesser, GA
Bayburt, EK
Bhagwat, SS
Stewart, AO
Yu, HX
Kohlhaas, KL
McGaraughty, S
Wismer, CT
Mikusa, J
Zhu, C
Alexander, KM
Jarvis, MF
Kowaluk, EA
Citation: M. Cowart et al., Structure-activity studies of 5-substituted pyridopyrimidines as adenosinekinase inhibitors, BIOORG MED, 11(1), 2001, pp. 83-86
Citation: Mf. Jarvis et Ea. Kowaluk, Pharmacological characterization of P2X(3) homomeric and heteromeric channels in nociceptive signaling and behavior, DRUG DEV R, 52(1-2), 2001, pp. 220-231
Authors:
Boyle, DL
Kowaluk, EA
Jarvis, MF
Lee, CH
Bhagwat, SS
Williams, M
Firestein, GS
Citation: Dl. Boyle et al., Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis, J PHARM EXP, 296(2), 2001, pp. 495-500
Authors:
McGaraughty, S
Chu, KL
Wismer, CT
Mikusa, J
Zhu, CZ
Cowart, M
Kowaluk, EA
Jarvis, MF
Citation: S. Mcgaraughty et al., Effects of a-134974, a novel adenosine kinase inhibitor, on carrageenan-induced inflammatory hyperalgesia and locomotor activity in rats: Evaluation of the sites of action, J PHARM EXP, 296(2), 2001, pp. 501-509
Authors:
Lee, CH
Jiang, MQ
Cowart, M
Gfesser, G
Perner, R
Kim, KH
Gu, YG
Williams, M
Jarvis, MF
Kowaluk, EA
Stewart, AO
Bhagwat, SS
Citation: Ch. Lee et al., Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor, J MED CHEM, 44(13), 2001, pp. 2133-2138
Authors:
Suzuki, R
Stanfa, LC
Kowaluk, EA
Williams, M
Jarvis, MF
Dickenson, AH
Citation: R. Suzuki et al., The effect of ABT-702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury, BR J PHARM, 132(7), 2001, pp. 1615-1623
Authors:
Jarvis, MF
Wismer, CT
Schweitzer, E
Yu, HX
van Biesen, T
Lynch, KJ
Burgard, EC
Kowaluk, EA
Citation: Mf. Jarvis et al., Modulation of BzATP and formalin induced nociception: attenuation by the P2X receptor antagonist, TNP-ATP and enhancement by the P2X(3) allosteric modulator, cibacron blue, BR J PHARM, 132(1), 2001, pp. 259-269
Authors:
Zhu, CZ
Mikusa, J
Chu, KL
Cowart, M
Kowaluk, EA
Jarvis, MF
McGaraughty, S
Citation: Cz. Zhu et al., A-134974: a novel adenosine kinase inhibitor, relieves tactile allodynia via spinal sites of action in peripheral nerve injured rats, BRAIN RES, 905(1-2), 2001, pp. 104-110
Authors:
Jarvis, MF
Yu, HX
Kohlhaas, K
Alexander, K
Lee, CH
Jiang, MQ
Bhagwat, SS
Williams, M
Kowaluk, EA
Citation: Mf. Jarvis et al., ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse, J PHARM EXP, 295(3), 2000, pp. 1156-1164
Authors:
Kowaluk, EA
Mikusa, J
Wismer, CT
Zhu, CZ
Schweitzer, E
Lynch, JJ
Lee, CH
Jiang, MQ
Bhagwat, SS
Gomtsyan, A
McKie, J
Cox, BF
Polakowski, J
Reinhart, G
Williams, M
Jarvis, MF
Citation: Ea. Kowaluk et al., ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat, J PHARM EXP, 295(3), 2000, pp. 1165-1174
Authors:
Hajduk, PJ
Gomtsyan, A
Didomenico, S
Cowart, M
Bayburt, EK
Solomon, L
Severin, J
Smith, R
Walter, K
Holzman, TF
Stewart, A
McGaraughty, S
Jarvis, MF
Kowaluk, EA
Fesik, SW
Citation: Pj. Hajduk et al., Design of adenosine kinase inhibitors from the NMR-based screening of fragments, J MED CHEM, 43(25), 2000, pp. 4781-4786
Citation: Mf. Jarvis et al., ABT-627, an endothelin ETA receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain, EUR J PHARM, 388(1), 2000, pp. 29-35
Authors:
Britton, DR
Mikusa, J
Lee, CH
Jarvis, MF
Williams, M
Kowaluk, EA
Citation: Dr. Britton et al., Site and event specific increase of striatal adenosine release by adenosine kinase inhibition in rats, NEUROSCI L, 266(2), 1999, pp. 93-96
Authors:
Yu, HX
Bianchi, B
Metzger, R
Lynch, KJ
Kowaluk, EA
Jawis, MF
van Biesen, T
Citation: Hx. Yu et al., Lack of specificity of [S-35]-ATP gamma S and [S-35]-ADP beta S as radioligands for ionotropic and metabotropic P2 receptor binding, DRUG DEV R, 48(2), 1999, pp. 84-93
Authors:
Kowaluk, EA
Kohlhaas, KL
Bannon, A
Gunther, K
Lynch, JJ
Jarvis, MF
Citation: Ea. Kowaluk et al., Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice, PHARM BIO B, 63(1), 1999, pp. 83-91
Authors:
Alexander, K
Niforatos, W
Bianchi, B
Burgard, EC
Lynch, KJ
Kowaluk, EA
Jarvis, MF
van Biesen, T
Citation: K. Alexander et al., Allosteric modulation and accelerated resensitization of human P2X(3) receptors by cibacron blue, J PHARM EXP, 291(3), 1999, pp. 1135-1142
Citation: Jl. Lynch et al., An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain, EUR J PHARM, 364(2-3), 1999, pp. 141-146